Want to see AU:LGP full AI Analyst Report?
LGP Stock Chart & Stats
AU$0.10
<AU$0.01(1.67%)
At close: 4:00 PM EST
AU$0.10
<AU$0.01(1.67%)
Day’s Range― - ―
52-Week RangeAU$0.06 - AU$0.14
Previous CloseN/A
Volume21.69K
Average Volume (3M)176.18K
Market Cap
AU$49.68M
Enterprise ValueAU$28.30T
Total Cash (Recent Filing)AU$1.42M
Total Debt (Recent Filing)AU$4.69M
Price to Earnings (P/E)―
Beta0.43
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding827,978,700
10 Day Avg. Volume210,499
30 Day Avg. Volume176,180
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)0.36
Price to Sales (P/S)0.70
P/FCF Ratio-37.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageConservative leverage gives LGP financial flexibility and reduces pressure from interest and refinancing obligations. Its sizeable equity base relative to debt provides capacity to absorb operating volatility and support investment in medicinal cannabis products and regulated-market expansion.
Long-term Revenue ScaleThe substantial multi-year increase in revenue shows that LGP has expanded its commercial scale and patient-market reach since 2020. A larger operating base can support broader product distribution and improve the potential for future operating leverage if profitability becomes more consistent.
Improving Cash BurnOperating cash flow reaching roughly breakeven represents a meaningful improvement from materially negative prior years. Although free cash flow remains negative, this trend suggests reduced operating cash consumption and provides a better foundation for the business to move toward self-funded operations.
Bears Say
Revenue ContractionThe latest revenue pullback interrupts LGP’s earlier growth trajectory and indicates that demand, market access, or product mix did not sustain the prior year’s level. Continued contraction would reduce scale benefits and make it harder to cover fixed operating costs across regulated markets.
Inconsistent ProfitabilityLGP has not yet demonstrated durable operating profitability: 2026 produced a net loss and negative EBIT, while 2025 earnings were positive despite negative operating profit. This volatility weakens earnings visibility and limits confidence in repeatable returns from the asset base.
Negative Free Cash FlowDespite improved cash-burn trends, LGP still did not fully fund investment and operations through internally generated cash in 2026. Persistent negative free cash flow can constrain reinvestment and, if improvement stalls, increase reliance on external capital to sustain growth.
Little Green Pharma Ltd. News
LGP FAQ
What was Little Green Pharma Ltd.’s price range in the past 12 months?
Little Green Pharma Ltd. lowest share price was AU$0.06 and its highest was AU$0.14 in the past 12 months.
What is Little Green Pharma Ltd.’s market cap?
Little Green Pharma Ltd.’s market cap is AU$49.68M.
When is Little Green Pharma Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Little Green Pharma Ltd.’s earnings last quarter?
Currently, no data Available
Is Little Green Pharma Ltd. overvalued?
According to Wall Street analysts Little Green Pharma Ltd.’s price is currently Overvalued.
Does Little Green Pharma Ltd. pay dividends?
Little Green Pharma Ltd. does not currently pay dividends.
What is Little Green Pharma Ltd.’s EPS estimate?
Little Green Pharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Little Green Pharma Ltd. have?
Little Green Pharma Ltd. has 827,978,700 shares outstanding.
What happened to Little Green Pharma Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Little Green Pharma Ltd.?
Currently, no hedge funds are holding shares in AU:LGP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Little Green Pharma Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.55%
12-Months-Change
Fundamentals
Return on Equity
-1.67%
Trailing 12-Months
Asset Growth
-2.46%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Little Green Pharma Ltd.
Little Green Pharma Ltd, established in 2016 and based in West Perth, Australia, specializes in the worldwide cultivation, manufacturing, and distribution of medicinal cannabis products. Its extensive product range encompasses cannabis flower medicines, various cannabis extracts, tinctures, and active pharmaceutical ingredients (APIs), serving markets both within Australia and internationally.
Technical Analysis
Elixinol Wellness
―
Cann Group
―
Althea Group Holdings Ltd.
―
Cronos Australia Ltd.
―